Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR12000 vs sacubitril-valsartan for moderate to severe essential hypertension
ChiCTR2500113274Phase 3Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QR12000 in essential hypertension (3 arms), sponsored by Peking University First Hospital. Primary endpoint: Change from baseline in office mean sitting systolic blood pressure (msSBP) and diastolic blood pressure (msDBP). Started Nov 2025; status: recruiting.
02
Drugs
QR12000
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2500113274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113274.